Current Edition

Custopharm

Hikma bolsters injectables franchise with $425M deal for Custopharm, but FTC review looms

Generics giant Hikma is boosting its injectables business to nearly 130 products in the U.S. by way of dealmaking. For $375 million upfront and another …

Continue Reading →
Federal Trade Commission

Sanofi refiles $3.2B Translate Bio buyout with FTC to allow more time for review

Ever since the Federal Trade Commission (FTC) unveiled its campaign to take a closer look at biopharma’s M&A strategies, the industry’s dealmakers have been on …

Continue Reading →